Medical News

RSS

PhRMA calls for appropriate incentives for continued biotechnology innovation

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:

20 Oct 2009

Teacher participation in research experience program produces a significaant increase in student achievement

The notion that training teachers in the rigors of hands-on science will directly improve their students' academic performance now has real data behind it: Research assembled over the last decade - now published in the Oct. 16 issue of Science - shows that high school students' pass rate on New York State standardized tests, called Regents examinations, can be significantly improved if they are among the lucky few to study under a teacher trained in Columbia University's Summer Research Program for Science Teachers.

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

Repligen Corporation reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the sensitivity and specificity of RG1068 in conjunction with MRI for the detection of pancreatic duct abnormalities compared to MRI alone.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Preliminary findings from EDC survey presented at DIA 3rd Annual Clinical Forum

Preliminary findings from a new survey on electronic data capture (EDC) use in clinical trials were presented today at the Drug Information Association's (DIA) 3rd Annual Clinical Forum in Nice, France. The survey, titled "Investigational Site Perspectives on Clinical Trial Information Systems," is the first update to a 2001 survey published on the topic.

20 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

20 Oct 2009

Medical Marijuana offers "Turnkey Collective Solution" for collectives to conform to state laws

Medical Marijuana, Inc. is the ONLY company that provides the specific solutions the government is seeking in order for all collectives and co-ops to be in total compliance with state laws and city/county ordinances. Their revolutionary patent pending Tax Remittance Card and patent pending Inventory Management System and Supply Chain Network provides all of the tools necessary for regulatory authorities and industry operators alike to manage compliance efficiently and effectively.

20 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

This study demonstrates that over 6 weeks of treatment, patients with melancholic depression and medical comorbidity (MC) (specifically cardiovascular or endocrinological MC) had poorer treatment response and a worse functional outcome as opposed to their counterparts without MC. Interestingly, these effects were not related to various antidepressant treatment regimens.

20 Oct 2009

Day care center integrates diabetes care for children into its routine as part of ADA settlement

Pine Hills Kiddie Garden of Fort Wayne, Ind., will take necessary steps to ensure that a child's diabetes care is integrated into the usual routine of its day care center and programs as part of a settlement to resolve allegations that it discriminated on the basis of disability, the Justice Department announced today.

20 Oct 2009

University of Leeds' £50 million research initiative to improve quality of life in second half century

A £50 million research initiative, aimed at giving people '50 active years after 50' is being launched by the University of Leeds.

20 Oct 2009

Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial

Detailed results from the Prime-Boost HIV Vaccine Clinical Trial involving more than 16,000 adult volunteers in Thailand show that an investigational HIV vaccine regimen was safe and modestly effective at reducing the rate of HIV infection compared to placebo.

20 Oct 2009

Swine flu outbreak at USAFA: Investigators study behavior of the nH1N1 virus

With the 2009 influenza season upon us, characterization of the epidemiology and duration of shedding for the nH1N1 virus is critical. Investigators from the U.S. Air Force Academy and the U.S. Air Force School of Aerospace Medicine Epidemiology Consult Service capitalized on a unique opportunity to gain valuable insights about the natural behavior of the nH1N1 virus, including shedding patterns, during a recent large-scale swine flu outbreak at the U.S. Air Force Academy (USAFA).

20 Oct 2009

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Focal nodular hyperplasia (FNH) is a lesion found in an otherwise normal liver, and is considered to be parenchyma overgrowth responsive to increased blood flow secondary to vascular malformations.

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

Alabama Supreme Court rules in favor of Novartis Pharmaceuticals

The Alabama Supreme Court today overturned a jury verdict against Novartis Pharmaceuticals Corporation (NPC), and directed entry of judgment in favor of NPC. NPC is pleased that the Alabama Supreme Court has found in our favor, which demonstrates that the State of Alabama's claims were unfounded.

20 Oct 2009

Medical News

PhRMA calls for appropriate incentives for continued biotechnology innovation

Teacher participation in research experience program produces a significaant increase in student achievement

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Preliminary findings from EDC survey presented at DIA 3rd Annual Clinical Forum

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

ImmunoCellular Therapeutics files a provisional patent application

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Medical Marijuana offers "Turnkey Collective Solution" for collectives to conform to state laws

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Study explores the efficacy of antidepressant drugs for patients with severe depression and medical disorder

Day care center integrates diabetes care for children into its routine as part of ADA settlement

University of Leeds' £50 million research initiative to improve quality of life in second half century

Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial

Swine flu outbreak at USAFA: Investigators study behavior of the nH1N1 virus

Clonality analyses may lead to further understanding of hepatocarcinogenesis

Biomagnetics Diagnostics to raise $1 million

Alabama Supreme Court rules in favor of Novartis Pharmaceuticals

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News